Search Results - "Riedel, Klaus‐Dieter"

Refine Results
  1. 1

    Trimethoprim–metformin interaction and its genetic modulation by OCT2 and MATE1 transporters by Grün, Barbara, Kiessling, Michael K., Burhenne, Jürgen, Riedel, KlausDieter, Weiss, Johanna, Rauch, Geraldine, Haefeli, Walter E., Czock, David

    Published in British journal of clinical pharmacology (01-11-2013)
    “…Aims Metformin pharmacokinetics depends on the presence and activity of membrane‐bound drug transporters and may be affected by transport inhibitors. The aim…”
    Get full text
    Journal Article
  2. 2

    Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype by Scholz, Ina, Oberwittler, Heike, Riedel, KlausDieter, Burhenne, Jürgen, Weiss, Johanna, Haefeli, Walter E., Mikus, Gerd

    Published in British journal of clinical pharmacology (01-12-2009)
    “…WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Pharmacokinetic variability of voriconazole is largely caused by CYP3A4‐ and CYP2C19‐mediated metabolism. • Oral…”
    Get full text
    Journal Article
  3. 3
  4. 4

    Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients by Yimer, Getnet, Ueda, Nobuhisa, Habtewold, Abiy, Amogne, Wondwossen, Suda, Akira, Riedel, Klaus-Dieter, Burhenne, Jürgen, Aderaye, Getachew, Lindquist, Lars, Makonnen, Eyasu, Aklillu, Eleni

    Published in PloS one (06-12-2011)
    “…Implication of pharmacogenetic variations and efavirenz pharmacokinetics in concomitant efavirenz based antiviral therapy and anti-tubercular drug induced…”
    Get full text
    Journal Article
  5. 5
  6. 6
  7. 7

    Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania by Mugusi, Sabina, Ngaimisi, Eliford, Janabi, Mohamed, Minzi, Omary, Bakari, Muhammad, Riedel, Klaus-Dieter, Burhenne, Juergen, Lindquist, Lars, Mugusi, Ferdinand, Sandstrom, Eric, Aklillu, Eleni

    Published in PloS one (11-07-2012)
    “…To investigate the timing, incidence, clinical presentation, pharmacokinetics and pharmacogenetic predictors for antiretroviral and anti-tuberculosis drug…”
    Get full text
    Journal Article
  8. 8

    Clarithromycin substantially increases steady‐state bosentan exposure in healthy volunteers by Markert, Christoph, Schweizer, Yvonne, Hellwig, Regina, Wirsching, Theresia, Riedel, KlausDieter, Burhenne, Juergen, Weiss, Johanna, Mikus, Gerd, Haefeli, Walter E.

    Published in British journal of clinical pharmacology (01-01-2014)
    “…Aims The aim of this study was to assess the effect of the cytochrome P450 (CYP) 3A4 and organic anion‐transporting polypeptide (OATP) 1B1 inhibitor…”
    Get full text
    Journal Article
  9. 9

    Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine by Grün, Barbara, Merkel, Ulrike, Riedel, KlausDieter, Weiss, Johanna, Mikus, Gerd

    Published in British journal of clinical pharmacology (01-11-2012)
    “…WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • The analgesic activity of tilidine is mediated by its active metabolite, nortilidine, which easily penetrates the…”
    Get full text
    Journal Article
  10. 10
  11. 11

    The NK1 receptor antagonist aprepitant does not alter the pharmacokinetics of high‐dose melphalan chemotherapy in patients with multiple myeloma by Egerer, Gerlinde, Eisenlohr, Kathrin, Gronkowski, Martina, Burhenne, Juergen, Riedel, KlausDieter, Mikus, Gerd

    Published in British journal of clinical pharmacology (01-12-2010)
    “…WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Nausea and vomiting are the most distressing side‐effects of a high dose melphalan regimen. • Aprepitant in addition…”
    Get full text
    Journal Article
  12. 12

    Modulators of Very Low Voriconazole Concentrations in Routine Therapeutic Drug Monitoring by HASSAN, Arwa, BURHENNE, Jürgen, RIEDEL, Klaus-Dieter, WEISS, Johanna, MIKUS, Gerd, HAEFELI, Waster E, CZOCK, David

    Published in Therapeutic drug monitoring (01-02-2011)
    “…Very low voriconazole concentrations are commonly observed during therapeutic drug monitoring. Possible mechanisms include inappropriate dose selection, rapid…”
    Get full text
    Journal Article
  13. 13

    Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers by Ding, Reinhard, Tayrouz, Yorki, Riedel, KlausDieter, Burhenne, Jürgen, Weiss, Johanna, Mikus, Gerd, Haefeli, Walter E.

    Published in Clinical pharmacology and therapeutics (01-07-2004)
    “…Background Ritonavir is a potent in vitro inhibitor of several cytochrome P450 isozymes and ABC transporters including the efflux pump P‐glycoprotein (P‐gp)…”
    Get full text
    Journal Article
  14. 14

    Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics by Rengelshausen, Jens, Banfield, Maria, Riedel, KlausDieter, Burhenne, Jürgen, Weiss, Johanna, Thomsen, Torben, Walter‐Sack, Ingeborg, Haefeli, Walter E., Mikus, Gerd

    Published in Clinical pharmacology and therapeutics (01-07-2005)
    “…Objectives Constituents of St John's wort (SJW) in vivo induce the cytochrome P450 (CYP) isozymes 3A4, 2C9, and 2C19 but in vitro were shown to inhibit them…”
    Get full text
    Journal Article
  15. 15
  16. 16

    Inhibition of the active principle of the weak opioid tilidine by the triazole antifungal voriconazole by Grün, Barbara, Krautter, Stefanie, Riedel, KlausDieter, Mikus, Gerd

    Published in British journal of clinical pharmacology (01-11-2009)
    “…WHAT IS ALREADY KNOWN ABOUT THE SUBJECT • Tilidine, a World Health Organization level II analgesic, is a high extraction drug subject to pronounced first‐pass…”
    Get full text
    Journal Article
  17. 17

    Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40 by Tayrouz, Yorki, Ding, Reinhard, Burhenne, Jürgen, Riedel, KlausDieter, Weiss, Johanna, Hoppe‐Tichy, Torsten, Haefeli, Walter Emil, Mikus, Gerd

    Published in Clinical pharmacology and therapeutics (01-05-2003)
    “…Background The pharmacokinetics of digoxin is modulated by the efflux pump P‐glycoprotein. Cremophor EL (BASF Aktiengesellschaft, Ludwigshafen, Germany)…”
    Get full text
    Journal Article
  18. 18
  19. 19
  20. 20

    Undeclared exposure to St. John's Wort in hospitalized patients by Martin‐Facklam, Meret, Rieger, Karin, Riedel, KlausDieter, Burhenne, Jürgen, Walter‐Sack, Ingeborg, Haefeli, Walter E.

    Published in British journal of clinical pharmacology (01-10-2004)
    “…Aim The herbal medicine St. John's Wort (SJW) causes substantial decreases in the plasma concentrations of a range of co‐administered drugs. Therefore, we…”
    Get full text
    Journal Article